Telehealth and COVID-19: Empowering Standards of Management for Patients Affected by Phenylketonuria and Hyperphenylalaninemia
Phenylketonuria (PKU) and Hyperphenylalaninemia (HPA) are inborn errors of metabolism (IEM) due to mutations in the <i>PAH</i> gene resulting in increased blood phenylalanine (Phe) concentrations. Depending on the Phe levels, a lifelong dietary intervention may be needed. During the COVI...
Guardado en:
Autores principales: | Valentina Rovelli, Juri Zuvadelli, Sabrina Paci, Vittoria Ercoli, Alice Re Dionigi, Raed Selmi, Elisabetta Salvatici, Graziella Cefalo, Giuseppe Banderali |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f58748ea40f0415aab514bad15139e0c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Preventing maternal phenylketonuria (PKU) syndrome: important factors to achieve good metabolic control throughout pregnancy
por: Carmen Rohde, et al.
Publicado: (2021) -
Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria
por: Iris Scala, et al.
Publicado: (2021) -
Italian national consensus statement on management and pharmacological treatment of phenylketonuria
por: Alberto Burlina, et al.
Publicado: (2021) -
A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials
por: Barbara K. Burton, et al.
Publicado: (2021) -
Improving phenylalanine and micronutrients status of children with phenylketonuria: a pilot randomized study
por: Reza Zamani, et al.
Publicado: (2021)